Using a newly developed LC-ESI-MS/MS method, mean plasma angiotensin II levels were 64.5 pM in CKD-5D patients and 18.4 pM in healthy subjects, with no significant difference between the groups.
Observational (n=18)
A newly developed LC-ESI-MS/MS method successfully quantified endogenous angiotensin II levels, demonstrating higher levels in CKD-5D patients compared to healthy volunteers.
Absolute Event Rate: 64.5% vs 18.4%
BACKGROUND: Angiotensin II acts as a peptide hormone and component of renin-angiotensin- system (RAS) regulating the blood pressure, and seems to be involved in renal and vascular disorders. There is no reliable quantification method for angiotensin II available until now and the angiotensin II plasma levels described in the literature are correspondingly strongly divergent. Therefore, we developed and validated a sensitive, selective and reliable LC-ESI-MS/MS method for absolute quantification of angiotensin II concentration in human plasma based on the AQUA strategy. METHODS: Plasma samples were extracted using MAX Oasis cartridges and were subjected to a further immunoaffinity-purification using immobilized anti-angiotensin II antibodies in order to isolate endogenous angiotensin II. Stable isotope ((13)C- and (15) N-) labeled angiotensin II was used as an internal standard. The fractionated samples were analysed using LC-ESI-MS/MS. RESULTS: The calibration curve was established in plasma in the concentration range 6-240 pM (r(2) > 0.999). The developed and validated method was successfully applied for quantification of endogenous angiotensin II in human plasma of healthy volunteers and chronic kidney disease (CKD-5D) patients. The mean plasma angiotensin II levels were found to be 18.4 ± 3.3 pM in healthy subjects and 64.5 ± 32.4 pM in CKD-5D patients (each n =9). CONCLUSION: The LC-ESI-MS/MS-based method for quantification of angiotensin II levels in human plasma was successfully evaluated within the study. This method is applicable for clinical applications aiming at the validation of the impact of highly physiologically and pathophysiologically active angiotensin II.
Schulz et al. (2014) conducted an observational in Chronic Kidney Disease (n=18). Chronic kidney disease (CKD-5D) vs. Healthy subjects was evaluated on Mean plasma angiotensin II levels (pM). Using a newly developed LC-ESI-MS/MS method, mean plasma angiotensin II levels were 64.5 pM in CKD-5D patients and 18.4 pM in healthy subjects, with no significant difference between the groups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: